24 May 2024
Futura Medical
plc
("Futura" or the
"Company")
Notice of AGM and
availability of Annual Report
Futura Medical plc (AIM:
FUM), the consumer healthcare company
behind Eroxon, that specialises in the development
and global commercialisation of innovative and clinically
proven sexual health products, today announces its Annual
General Meeting ("AGM") will be held at 10:00am on Thursday, 20
June 2024 at the offices of Liberum Capital Limited, Ropemaker
Place, 25 Ropemaker Street, London EC2Y 9LY.
If you wish to attend the meeting in
person, please register your interest, prior to 10:00am on Monday
17 June 2024, at investor.relations@futuramedical.com.
Shareholders are asked to cast their
vote as follows: (1) casting your proxy vote online via the Link
Investor Centre app or by accessing the web browser at
https://investorcentre.linkgroup.co.uk/Login/Login
and following the instructions; or (2) in the case
of CREST members, by utilising the CREST electronic proxy
appointment service; or (3) if you are an institutional investor
you may also be able to appoint a proxy electronically via the
Proxymity platform; or (4) requesting a hard copy form of proxy
directly from the registrars, Link Group. If you choose to attend
the Annual General Meeting in person instead of appointing the
Chairman of the meeting as proxy, as we strongly recommend, you
will still be able to vote in person at the Annual General
Meeting.
If you are not attending the Annual
General Meeting in person, your proxy vote will need to be
logged
by 10:00am on Tuesday 18 June 2024,
as no online voting will take place in-real time during the meeting
itself.
The Board will make arrangements for
shareholders to listen to proceedings remotely should they wish to
do so. You can request access by emailing:
investor.relations@futuramedical.com prior to 10:00 a.m. on 17 June
2024. Shareholders will not get an opportunity to vote or ask
questions or participate in any other way during the
call.
Annual Report
Futura's annual report and accounts
for the year ended 31 December 2023 (the "Annual Report") is
available to shareholders as an electronic communication pursuant
to the Companies Act 2006 and is now available on the Company's
website www.futuramedical.com,
along with the Notice of AGM.
Contacts:
|
Futura Medical plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
|
Liberum
Nominated Adviser
and Broker
|
Phil Walker
Richard Lindley
Nikhil Varghese
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Stifel Nicolaus Europe Limited
Joint Broker
|
Alan Selby
Ben Maddison
|
+44 (0)207 710 7600
|
|
|
|
|
|
Alma Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the
developer of innovative sexual health products, including lead
product Eroxon. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in
sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten
minutes, addresses significant unmet needs in the ED
market.
ED impacts 1 in 5 men globally
across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men
under 40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper Consumer
Health in Europe. Eroxon has been nominated for a number of
healthcare industry awards and has won two to-date.
